CNS

News

Positive Ph1 results for AC Immune's NLRP3 inflammasome inhi...

AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.

R&D

An elderly woman holds her hand to stop shaking

Parkinson’s Awareness Month may end, but the research impera...

As Parkinson’s Awareness Month comes to a close, the urgency to challenge the status quo has never been greater.

R&D

Innovative direct delivery strategies to unlock oligonucleot...

Oligo therapies are emerging as promising therapeutics with the potential to address previously untreatable conditions.

R&D

Neuroplasticity modulators as innovative potential disease-m...

In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome

Digital

Everyday drug discovery: How tech expands the potential of c...

Discover how technology is making clinical trials more flexible and patient-friendly through tools like eCOA, eConsent, and wearables.

Patients

Real-world evidence in CNS research: Past, present, future

Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.

Positive Ph1 results for AC Immune's NLRP3 inflammasome inhi...

Parkinson’s Awareness Month may end, but the research impera...

Innovative direct delivery strategies to unlock oligonucleot...

Neuroplasticity modulators as innovative potential disease-m...

Everyday drug discovery: How tech expands the potential of c...

Real-world evidence in CNS research: Past, present, future

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

CNS

Editor's Picks